Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | PRKX | P51817 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3109957 | 0.99 | S1PR1 (0.52) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| SCHEMBL3112604 | 0.97 | S1PR1 (0.52) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| Hydrochloric Acid SCHEMBL3120105 | 0.96 | S1PR1 (0.52) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| SCHEMBL5793202 | 0.94 | S1PR1 (0.57) | S1PR1S1PR3PRKXACVR1S1PR5 | |
| SCHEMBL777075 | 0.94 | S1PR1 (0.60) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| Hydrochloric Acid SCHEMBL3122033 | 0.93 | S1PR1 (0.59) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| SCHEMBL3110012 | 0.92 | S1PR1 (0.45) | S1PR1S1PR3MAOB | |
| SCHEMBL3513167 | 0.91 | S1PR1 (0.48) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| SCHEMBL3107537 | 0.91 | S1PR1 (0.44) | S1PR1S1PR3FFAR1FFAR4MAOB | |
| SCHEMBL3510909 | 0.91 | S1PR1 (0.48) | S1PR1S1PR3CYP4F2CYP4A11PRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1944026-B1 | Use of EDG receptor binding agents in cancer | NOVARTIS AG (CH) | 2013-06-26 | — | — | EP | claimed |
| US-8324283-B2 | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | claimed |
| US-20110224239-A1 | Combinations Comprising a S1P Receptor Agonist and a JAK3 Kinase Inhibitor | LAKE PHILIP | 2011-09-15 | — | — | US | claimed |
| EP-2363149-A1 | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor | Novartis AG (CH) | 2011-09-07 | — | — | EP | claimed |
| EP-1431275-B1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | KYORIN SEIYAKU KK (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20090163523-A1 | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor | LAKE PHILIP | 2009-06-25 | — | — | US | claimed |
| EP-2008650-A2 | Solid oral composition comprising a S 1 P receptor agonist and a sugar alcohol | Novartis AG (CH) | 2008-12-31 | — | — | EP | claimed |
| US-20080311188-A1 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A SIP RECEPTOR AGONIST AND A SUGAR ALCOHOL | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | claimed |
| US-20080221200-A1 | Combination of Organic Compounds | ALLISON MALCOLM | 2008-09-11 | — | — | US | claimed |
| US-20080206240-A1 | Antilymphocyte Antibody Induction | ARADHYE SHREERAM | 2008-08-28 | — | — | US | claimed |
| EP-1940388-A2 | DPP IV INHIBTOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION | Novartis AG (CH) | 2008-07-09 | — | — | EP | claimed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | claimed |
| EP-1915994-A1 | CYCLIC AMINE DERIVATIVE CONTAINING PPAR REGULATOR | Sankyo Company, Limited (JP) | 2008-04-30 | — | — | EP | claimed |
| WO-2007041368-A2 | DPP IV INHIBITOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | claimed |
| EP-1755680-A1 | COMBINATIONS COMPRISING A S1P RECEPTOR AGONIST AND A JAK3 KINASE INHIBITOR | Novartis AG (CH) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105146-A1 | COMBINATIONS COMPRISING A S1P RECEPTOR AGONIST AND A JAK3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2005-11-10 | — | — | WO | claimed |
| US-6963012-B2 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | claimed |
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | claimed |
| EP-1431275-A1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | claimed |
| EP-4637819-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND S1PR INHIBITORS | Prometheus Biosciences, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024137353-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND S1PR INHIBITORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20200237690-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-20190175527-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| EP-2142184-B1 | USE OF S1P RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-20170290787-A1 | Organic Compounds | NOVARTIS AG (CH) | 2017-10-12 | — | — | US | disclosed |
| EP-1915130-B1 | LIQUID FORMULATIONS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-20160101179-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | BURANACHOKPAISAN THITIWAN (US) | 2016-04-14 | — | — | US | disclosed |
| US-9265754-B2 | Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20160030572-A1 | LIQUID FORMULATIONS | NOVARTIS AG (CH) | 2016-02-04 | — | — | US | disclosed |
| EP-2316431-B1 | Solid oral composition comprising a S1P receptor agonist and a sugar alcohol | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-20150080347-A9 | LIQUID FORMULATIONS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | disclosed |
| EP-2829268-A1 | Compound formulations of 2-amino-1,3-propanediol compounds | Novartis AG (CH) | 2015-01-28 | — | — | EP | disclosed |
| EP-2255798-B1 | FTY720 for use in the treatment of optic neuritis | NOVARTIS AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| EP-1773307-B1 | COMPOUND FORMULATIONS OF 2-AMINO-1,3-PROPANEDIOL COMPOUNDS | NOVARTIS AG (CH) | 2014-10-15 | — | — | EP | disclosed |
| US-20140303257-A1 | Use of EDG Receptor Binding Agents in Cancer | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140271541-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| EP-2769713-A1 | Solid oral composition comprising a S1P receptor agonist and a sugar alcohol | Novartis AG (CH) | 2014-08-27 | — | — | EP | disclosed |
| US-20140235610-A1 | USE OF S1P RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| EP-1819326-B1 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST | NOVARTIS AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-20140179636-A1 | LIQUID FORMULATIONS | NOVARTIS AG (CH) | 2014-06-26 | — | — | US | disclosed |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | disclosed |
| EP-1955696-B1 | Use of the EDG receptor binding agent FTY720 in cancer | NOVARTIS AG (CH) | 2014-05-28 | — | — | EP | disclosed |
| US-20140094522-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | NOVARTIS AG (CH) | 2014-04-03 | — | — | US | disclosed |
| EP-2213285-B1 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20130281541-A1 | USE IN BRAIN DEGENERATIVE DISEASES | BRINKMANN VOLKER (DE) | 2013-10-24 | — | — | US | disclosed |
| US-8519006-B2 | Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-1944026-B1 | Use of EDG receptor binding agents in cancer | NOVARTIS AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| US-20130108675-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130065954-A1 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20120328664-A1 | LIQUID FORMULATIONS | GEORGOUSIS VIVIAN (US) | 2012-12-27 | — | — | US | disclosed |
| US-8324283-B2 | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120245129-A1 | USE OF S1P RECEPTOR MODULATOR | BARDE YVES-ALAIN (CH) | 2012-09-27 | — | — | US | disclosed |
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225031-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | FOSTER CAROLYN ANN (AT) | 2012-09-06 | — | — | US | disclosed |
| EP-2384749-A1 | Dosage regimen of an S1P receptor agonist | Novartis AG (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20110224239-A1 | Combinations Comprising a S1P Receptor Agonist and a JAK3 Kinase Inhibitor | LAKE PHILIP | 2011-09-15 | — | — | US | disclosed |
| EP-2363149-A1 | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor | Novartis AG (CH) | 2011-09-07 | — | — | EP | disclosed |
| EP-2359821-A1 | Dosage regimen of an s1p receptor agonist | Novartis AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| EP-2351560-A1 | Treatment Of HCV infections with FTY720 | Novartis AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20110136739-A1 | Use of S1P Receptor Agonists in Heart Diseases | BRINKMANN VOLKER | 2011-06-09 | — | — | US | disclosed |
| US-20110124739-A1 | Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative Diseases | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| EP-2319502-A1 | Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316431-A1 | Solid oral composition comprising a S1P receptor agonist and a sugar alcohol | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-7910626-B2 | Use of S1P receptor agonists in heart diseases | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-20100317627-A1 | Treatment of HCV Disorders | BRINKMANN VOLKER | 2010-12-16 | — | — | US | disclosed |
| EP-2255798-A2 | Sphingosine-1-phosphate receptor agonists for use in the treatment of optic neuritis | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-2251007-A2 | Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2216019-A2 | Ophthalmic uses of S1P receptor modulators | Novartis AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-2213285-A2 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100093672-A1 | USE OF S1P RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2142184-A1 | USE OF S1P RECEPTOR MODULATOR | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-20090324542-A1 | optic neuritis; fingolimod or 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol or salts as SP1 agonist | FOSTER CAROLYN ANN | 2009-12-31 | — | — | US | disclosed |
| US-20090275553-A1 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST | KOVARIK JOHN M | 2009-11-05 | — | — | US | disclosed |
| US-20090209495-A1 | USE OF EDG RECEPTOR BINDING AGENTS IN CANCER | BAUMRUKER THOMAS | 2009-08-20 | — | — | US | disclosed |
| US-20090203798-A1 | Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol | OOMURA TOMOYUKI | 2009-08-13 | — | — | US | disclosed |
| US-20090163523-A1 | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor | LAKE PHILIP | 2009-06-25 | — | — | US | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20090029922-A1 | Use of S1P receptor agonists in heart diseases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-2008650-A2 | Solid oral composition comprising a S 1 P receptor agonist and a sugar alcohol | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20080311188-A1 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A SIP RECEPTOR AGONIST AND A SUGAR ALCOHOL | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1613288-B1 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL | NOVARTIS AG (CH) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008135522-A1 | USE OF S1P RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2008-11-13 | — | — | WO | disclosed |
| US-20080221200-A1 | Combination of Organic Compounds | ALLISON MALCOLM | 2008-09-11 | — | — | US | disclosed |
| US-20080207739-A1 | Ophthalmic Uses of S1p Receptor Modulators | LAMBROU GEORGE N | 2008-08-28 | — | — | US | disclosed |
| US-20080207567-A1 | Treatment of Hcv Disorders | BRINKMANN VOLKER | 2008-08-28 | — | — | US | disclosed |
| US-20080206240-A1 | Antilymphocyte Antibody Induction | ARADHYE SHREERAM | 2008-08-28 | — | — | US | disclosed |
| US-20080194526-A1 | Concentrate comprising a S1P receptor agonist selected from 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propane-diol, and 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}azetidine-3-carboxylic acid | GEORGOUSIS VIVIAN | 2008-08-14 | — | — | US | disclosed |
| EP-1955696-A2 | Use of EDG receptor binding agents in cancer | Novartis AG (CH) | 2008-08-13 | — | — | EP | disclosed |
| EP-1944026-A2 | Use of EDG receptor binding agents in cancer | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| EP-1940388-A2 | DPP IV INHIBTOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION | Novartis AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080139662-A1 | Such as 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | BRINKMANN VOLKER | 2008-06-12 | — | — | US | disclosed |
| EP-1915994-A1 | CYCLIC AMINE DERIVATIVE CONTAINING PPAR REGULATOR | Sankyo Company, Limited (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1915130-A2 | LIQUID FORMULATIONS | Novartis AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| US-20080096972-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | BURANACHOKPAISAN THITIWAN | 2008-04-24 | — | — | US | disclosed |
| EP-1861081-A1 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| EP-1850865-A2 | ANTILYMPHOCYTE ANTIBODY INDUCTION BY COMBINATION OF AN S1P RECEPTOR AGONIST/MODULATOR AND OF IMMUNOSUPPRESSIVE DRUGS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| EP-1835899-A1 | TREATMENT OF HCV DISORDERS | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1819326-A1 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST | Novartis AG (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1773307-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1,3-PROPANEDIOL COMPOUNDS | Novartis AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007041368-A2 | DPP IV INHIBITOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| EP-1755680-A1 | COMBINATIONS COMPRISING A S1P RECEPTOR AGONIST AND A JAK3 KINASE INHIBITOR | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007021666-A2 | LIQUID FORMULATIONS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20060275357-A1 | Organic compounds | OOMURA TOMOYUKI | 2006-12-07 | — | — | US | disclosed |
| EP-1713459-A2 | USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES | Novartis AG (CH) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006094705-A1 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006086361-A2 | ANTILYMPHOCYTE ANTIBODY INDUCTION BY COMBINATION OF AN SlP RECEPTOR AGONIST/MODULATOR AND OF IMMUNOSUPPRESSIVE DRUGS | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006072562-A1 | TREATMENT OF HCV DISORDERS | NOVARTIS AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006058316-A1 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | disclosed |
| EP-1431275-A4 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | KYORIN SEIYAKU KK (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060046979-A1 | Combination therapy of sphingosine-1-phosphate (S1P) receptor agonist and coagent for treating demylination disease | FOSTER CAROLYN A | 2006-03-02 | — | — | US | disclosed |
| WO-2006010630-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
| EP-1613288-A1 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A S1P RECEPTOR AGONIST AND A SUGAR ALCOHOL | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005105146-A1 | COMBINATIONS COMPRISING A S1P RECEPTOR AGONIST AND A JAK3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-6963012-B2 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050222092-A1 | Use of s1p receptor agonists in heart diseases | BRINKMANN VOLKER | 2005-10-06 | — | — | US | disclosed |
| US-20050215531-A1 | Use of edg receptor binding agents in cancer | BAUMRUKER THOMAS | 2005-09-29 | — | — | US | disclosed |
| EP-1575576-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005058295-A2 | USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| EP-1505959-A1 | USE OF EDG RECEPTOR BINDING AGENTS IN CANCER | Novartis AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| WO-2004089341-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004028521-A2 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004010987-A2 | USE OF S1P RECEPTOR AGONISTS IN HEART DISEASES | NOVARTIS AG (CH) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003097028-A1 | USE OF EDG RECEPTOR BINDING AGENTS IN CANCER | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003029184-A1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003029184-A1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (44 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311188-A1 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A SIP RECEPTOR AGONIST AND A SUGAR ALCOHOL | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 4019/4885 |
| US-20190175527-A1 | ORGANIC COMPOUNDS | GPR119, OPRM1, FFAR1 | S1PR1 33/4885S1PR3 101/4885CYP4F2 686/4885 |
| US-20080096972-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | ACMSD, AASDHPPT, DDC | S1PR1 1198/4885S1PR3 937/4885CYP4F2 1769/4885 |
| US-20090203798-A1 | Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol | GPR119, SUCNR1, TAS1R1 | S1PR1 5/4885S1PR3 12/4885CYP4F2 4230/4885 |
| US-20160030572-A1 | LIQUID FORMULATIONS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885CYP4F2 3049/4885 |
| US-20090324542-A1 | optic neuritis; fingolimod or 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol or salts as SP1 agonist | SP1, S1PR2, S1PR1 | S1PR1 3/4885S1PR3 5/4885CYP4F2 3375/4885 |
| US-20110124739-A1 | Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative Diseases | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 4498/4885 |
| US-20120225031-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR3 4/4885CYP4F2 4478/4885 |
| US-20060275357-A1 | Organic compounds | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 1132/4885 |
| US-20090209495-A1 | USE OF EDG RECEPTOR BINDING AGENTS IN CANCER | S1PR3, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 1/4885CYP4F2 2774/4885 |
| US-20140235610-A1 | USE OF S1P RECEPTOR MODULATOR | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR3 5/4885CYP4F2 3385/4885 |
| US-20050215531-A1 | Use of edg receptor binding agents in cancer | S1PR3, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 1/4885CYP4F2 2774/4885 |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | PPARG, PPARA, PPARD | S1PR1 282/4885S1PR3 281/4885CYP4F2 470/4885 |
| US-20050222092-A1 | Use of s1p receptor agonists in heart diseases | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 3900/4885 |
| US-20090163523-A1 | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor | S1PR3, S1PR1, JAK3 | S1PR1 2/4885S1PR3 1/4885CYP4F2 3679/4885 |
| US-20140179636-A1 | LIQUID FORMULATIONS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885CYP4F2 3049/4885 |
| US-20130065954-A1 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS | S1PR5, S1PR2, S1PR1 | S1PR1 3/4885S1PR3 4/4885CYP4F2 3925/4885 |
| US-20100317627-A1 | Treatment of HCV Disorders | S1PR1, S1PR4, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 2548/4885 |
| US-20080221200-A1 | Combination of Organic Compounds | DPP4, DPP3, DPP7 | S1PR1 1727/4885S1PR3 1326/4885CYP4F2 926/4885 |
| US-20080139662-A1 | Such as 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | S1PR2, S1PR1, S1PR3 | S1PR1 2/4885S1PR3 3/4885CYP4F2 3931/4885 |
| US-20080207739-A1 | Ophthalmic Uses of S1p Receptor Modulators | S1PR5, S1PR2, S1PR1 | S1PR1 3/4885S1PR3 4/4885CYP4F2 3925/4885 |
| US-20120245129-A1 | USE OF S1P RECEPTOR MODULATOR | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885CYP4F2 3456/4885 |
| US-20100093672-A1 | USE OF S1P RECEPTOR MODULATOR | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR3 5/4885CYP4F2 3385/4885 |
| US-20130108675-A1 | ORGANIC COMPOUNDS | GPR119, OPRM1, FFAR1 | S1PR1 33/4885S1PR3 101/4885CYP4F2 686/4885 |
| US-20090029922-A1 | Use of S1P receptor agonists in heart diseases | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 3900/4885 |
| US-20130281541-A1 | USE IN BRAIN DEGENERATIVE DISEASES | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 4774/4885 |
| US-20060046979-A1 | Combination therapy of sphingosine-1-phosphate (S1P) receptor agonist and coagent for treating demylination disease | S1PR1, S1PR4, S1PR2 | S1PR1 1/4885S1PR3 4/4885CYP4F2 3374/4885 |
| US-20080194526-A1 | Concentrate comprising a S1P receptor agonist selected from 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propane-diol, and 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}azetidine-3-carboxylic acid | S1PR2, S1PR1, S1PR3 | S1PR1 2/4885S1PR3 3/4885CYP4F2 3269/4885 |
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | IL2, TSLP, HLA-DRB1 | S1PR1 927/4885S1PR3 776/4885CYP4F2 218/4885 |
| US-20090275553-A1 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR3 5/4885CYP4F2 1021/4885 |
| US-20120328664-A1 | LIQUID FORMULATIONS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885CYP4F2 3049/4885 |
| US-20140271541-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR3 4/4885CYP4F2 4478/4885 |
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR3 5/4885CYP4F2 1021/4885 |
| US-20140094522-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | ACMSD, AASDHPPT, DDC | S1PR1 1198/4885S1PR3 937/4885CYP4F2 1769/4885 |
| US-20110224239-A1 | Combinations Comprising a S1P Receptor Agonist and a JAK3 Kinase Inhibitor | S1PR3, S1PR1, JAK3 | S1PR1 2/4885S1PR3 1/4885CYP4F2 3679/4885 |
| US-20080207567-A1 | Treatment of Hcv Disorders | S1PR1, S1PR4, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 2548/4885 |
| US-20110136739-A1 | Use of S1P Receptor Agonists in Heart Diseases | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 3774/4885 |
| US-20170290787-A1 | Organic Compounds | GPR119, OPRM1, FFAR1 | S1PR1 33/4885S1PR3 101/4885CYP4F2 686/4885 |
| US-20160101179-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | ACMSD, AASDHPPT, DDC | S1PR1 1409/4885S1PR3 1018/4885CYP4F2 2051/4885 |
| US-20150080347-A9 | LIQUID FORMULATIONS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885CYP4F2 3049/4885 |
| US-20140303257-A1 | Use of EDG Receptor Binding Agents in Cancer | S1PR3, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 1/4885CYP4F2 3020/4885 |
| US-20080206240-A1 | Antilymphocyte Antibody Induction | CD4, M6PR, SELPLG | S1PR1 13/4885S1PR3 40/4885CYP4F2 2595/4885 |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885CYP4F2 4774/4885 |
| US-20200237690-A1 | ORGANIC COMPOUNDS | GPR119, OPRM1, FFAR1 | S1PR1 33/4885S1PR3 101/4885CYP4F2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.